期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 54, 期 12, 页码 1041-1057出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2009.04.084
关键词
pharmacogenetics; polymorphism; antithrombotic therapy
资金
- GlaxoSmithKline
- Otsuka
- Eli Lilly Co.
- Daiichi Sankyo, Inc.
- The Medicines Company
- Portola
- Accumetrics
- Schering-Plough
- AstraZeneca
- Eisai
- Baxter
Thrombosis is the most important underlying mechanism of coronary artery disease and embolic stroke. Hence, antithrombotic therapy is widely used in these scenarios. However, not all patients achieve the same degree of benefit from antithrombotic agents, and a considerable number of treated patients will continue to experience a new thrombotic event. Such lack of clinical benefit may be related to a wide variability of responses to antithrombotic treatment among individuals (i.e., interindividual heterogeneity). Several factors have been identified in this interindividual heterogeneity in response to antithrombotic treatment. Pharmacogenetics has emerged as a field that identifies specific gene variants able to explain the variability in patient response to a given drug. Polymorphisms affecting the disposition, metabolism, transporters, or targets of a drug all can be implicated in the modification of an individual's antithrombotic drug response and therefore the safety and efficacy of the aforementioned drug. The present paper reviews the modulating role of different polymorphisms on individuals' responses to antithrombotic drugs commonly used in clinical practice. (J Am Coll Cardiol 2009; 54: 1041-57) (C) 2009 by the American College of Cardiology Foundation
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据